mRNA Flu Vaccine Tops Standard Shot in Trial



(MedPage Today) — A quadrivalent modified mRNA influenza vaccine was more efficacious than a standard quadrivalent inactivated flu vaccine, a randomized phase III trial showed.
During the 2022-2023 flu season among people ages 18 to 64, the relative…



Source link : https://www.medpagetoday.com/infectiousdisease/uritheflu/118607

Author :

Publish date : 2025-11-19 22:00:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version